Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013

Sagara Y., Freedman R. A., Wong S. M., Aydogan F., Nguyen A., Barry W. T., ...More

BREAST CANCER RESEARCH AND TREATMENT, vol.166, no.2, pp.583-592, 2017 (SCI-Expanded) identifier identifier identifier


Breast-conserving surgery (BCS) followed by radiotherapy (RT) with or without endocrine therapy (ET) is a standard treatment option for ductal carcinoma in situ (DCIS). We sought to investigate national patterns in the use of adjuvant therapy after BCS for hormone receptor (HR)-positive DCIS over time.